KR930702985A - Treatment of Esophageal Cancer - Google Patents

Abstract

The present invention relates to a method of treating esophageal cancer in humans by administering an effective amount of a water-soluble camptothecin derivative compound to a person suffering from esophageal cancer.

Description

Treatment of Esophageal Cancer

Since this is an open matter, no full text was included.

Claims (30)

A method of treating esophageal cancer in a human by administering an effective amount of a compound of the formula: or a pharmaceutically acceptable salt, hydrate or solvate thereof to a person suffering from esophageal cancer: Wherein a) X is hydroxy and R is trimethylammoniummethyl, b) X is hydroxy and R is N-methylpiperazinylmethyl, or c) X is hydroxy and R is N-methylanilinomithyl Or d) X is hydroxy and R is cyclohexylaminomethyl, or e) X is hydroxy and R is N, N-dimethylaminoethyloxymethyl, or f) X is hydroxy and R is cyclopropylaminomethyl Or g) X is hydroxy and R is morpholinomethyl, h) X is hydroxy and R is aminomethyl, i) X is hydroxy and R is cyanomethyl, or j) X is hydroxy And R is dimethylaminomethyl. The method of claim 1 wherein the administration is oral. The method of claim 1, wherein the administration is parenteral. The method of claim 3, wherein the treatment used is from about 0.5 to about 25.0 mg / body surface area m ² / day for about 1 to about 5 days in a row. The method of claim 4, wherein the treatment used is from about 1.0 to about 2.5 mg / body surface area m ² / day for about 5 consecutive days. The method of claim 5, wherein the treatment used is from about 1.5 to about 2 mg / body surface area m ² / day for about 5 consecutive days. The method of claim 4, wherein the treatment is repeated at least once at intervals of about 7 days to about 28 days. The method of claim 5, wherein the treatment is repeated at least once at intervals of about 7 days to about 28 days. The method of claim 6, wherein the treatment is repeated at least once at intervals of about 7 days to about 28 days. The method of claim 2, wherein the administration is by short or long time intravenous infusion. The method of claim 10, wherein the administration is a 30 minute intravenous infusion. The method of claim 10, wherein the administration is a 24 hour intravenous infusion. The method of claim 3, wherein the treatment used is from about 1.0 to about 50.0 mg / body surface area m ² / day for about 1 to about 5 consecutive days. The method of claim 13, wherein the treatment used is from about 1.5 to about 5.0 mg / body surface area m ² / day for about 5 consecutive days. The method of claim 13, wherein the treatment is repeated at least once at intervals of about 7 days to about 28 days. The method of claim 14, wherein the treatment is repeated at least once at intervals of about 7 days to about 28 days. The method of claim 1 wherein the compound is topodecane. The method of claim 10, wherein the compound is topodecane. Use of a compound of the general formula: or a pharmaceutically acceptable salt, hydrate or solvate thereof for the manufacture of a medicament for the treatment of esophageal cancer: Wherein a) X is hydroxy and R is trimethylammoniummethyl, b) X is hydroxy and R is N-methylpiperazinylmethyl, or c) X is hydroxy and R is N-methylanilinomithyl Or d) X is hydroxy and R is cyclohexylaminomethyl, or e) X is hydroxy and R is N, N-dimethylaminoethyloxymethyl, or f) X is hydroxy and R is cyclopropylaminomethyl Or g) X is hydroxy and R is morpholinomethyl, h) X is hydroxy and R is aminomethyl, i) X is hydroxy and R is cyanomethyl, or j) X is hydroxy And R is dimethylaminomethyl. Use according to claim 19, wherein the medicament is used for oral administration. 20. The use of claim 19, wherein the medicament is used for parenteral administration. The use of claim 19, wherein the compound is topodecane. The use of claim 20, wherein the compound is topodecane. The use of claim 21, wherein the compound is topodecane. A pharmaceutical composition containing a compound of the formula: or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in treating human esophageal cancer: Wherein a) X is hydroxy and R is trimethylammoniummethyl, b) X is hydroxy and R is N-methylpiperazinylmethyl, or c) X is hydroxy and R is N-methylanilinomithyl Or d) X is hydroxy and R is cyclohexylaminomethyl, or e) X is hydroxy and R is N, N-dimethylaminoethyloxymethyl, or f) X is hydroxy and R is cyclopropylaminomethyl Or g) X is hydroxy and R is morpholinomethyl, h) X is hydroxy and R is aminomethyl, i) X is hydroxy and R is cyanomethyl, or j) X is hydroxy And R is dimethylaminomethyl. The composition of claim 25 used for oral administration. The composition of claim 25 used for parenteral administration. The composition of claim 25, wherein the compound is topodecane. The composition of claim 26, wherein the compound is topodecane. The composition of claim 27 wherein the compound is topodecan. ※ Note: The disclosure is based on the initial application.